Clinical Trials · NCT02974907
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- ReGenTree, LLC
- Enrollment
- 601
- Start date
- Nov 2016
- Locations
- 1 site, United States
- Primary endpoint
- Ocular Discomfort